How do I set a price alert for PFE.TO?

To set a PFE.TO price alert on Stock Alarm Pro, navigate to the PFE.TO quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for PFE.TO?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for PFE.TO. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for PFE.TO?

Stock Alarm Pro supports over 125 trigger types for PFE.TO: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about PFE.TO price changes?

PFE.TO alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for PFE.TO alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for PFE.TO and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

PFE.TO Company Intelligence - Business Model, Drivers & Risks

PFE.TO(PFE.TO)

$12.62—Stale · unknown old

WatchlistChart

PFE.TO(PFE.TO)

TSX • Last print unknown agoAbout this dataData status

$12.62—Stale · unknown old

WatchlistChart Studio

PFE.TO(PFE.TO)

PFE.TO

Pfizer Inc. is a leading global biopharmaceutical company based in New York, specializing in the development and manufacturing of innovative medicines and vaccines. Its competitive position is bolstered by a diverse product portfolio, including the widely recognized COVID-19 vaccine Comirnaty, and a strong pipeline of therapies targeting oncology, immunology, and rare diseases.

HealthcareDrug Manufacturers - Generalmoderate - Pfizer has a mix of fixed and variable costs, with significant investments in R&D and marketing, but also benefits from economies of scale in manufacturing.

Business Overview

01Vaccines (estimated 30% of total revenue)

02Oncology treatments (estimated 25% of total revenue)

03Rare disease therapies (estimated 20% of total revenue)

Pfizer generates revenue primarily through the sale of patented pharmaceuticals and vaccines, leveraging its strong R&D capabilities and extensive distribution network. The company benefits from pricing power in its therapeutic areas, particularly in oncology and specialty medicines, where competition is limited and demand is high.

What Moves the Stock

Approval and launch of new drugs, particularly in oncology and rare diseases

Sales performance of COVID-19 related products, including vaccines and treatments

Regulatory changes impacting drug pricing and patent protections

Partnerships and collaborations that enhance product offerings

Watch on Earnings

Total revenue growthNet income marginsR&D spending as a percentage of revenue

Risk Factors

Regulatory changes that could impact drug pricing and market access

Technological disruption in drug development and delivery methods

Increased competition from generic drugs and biosimilars

Emerging biotech firms with innovative therapies

Moderate debt levels relative to equity could limit financial flexibility

Potential pension obligations impacting cash flow

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - Pfizer's performance is somewhat linked to GDP growth, as healthcare spending tends to rise in stronger economic conditions, but demand for essential medicines remains stable even in downturns.

Interest Rates

Higher interest rates could increase Pfizer's financing costs for R&D and acquisitions, potentially dampening growth prospects and affecting valuation multiples.

Credit

minimal - Pfizer's strong balance sheet and cash flow generation reduce reliance on external credit.

Live Conditions

Russell 2000 FuturesDow Jones FuturesS&P 500 Futures